Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination

Equillium, Inc.

2024-Q3 EPS reported -$0.06 revenue$36,703,000

Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.
Cash $25.9M; sufficient into Q4 2025 assuming accelerated EQUATOR study, pausing EQ101/EQ302, and cost reductions.
Ono partnership ended after substantial non-dilutive funding; Equillium retains full rights to itolizumab.
Phase 3 EQUATOR aGVHD study enrollment paused; potential topline acceleration to Q1 2025.
Partner Biocon completed Phase 2 ulcerative colitis study; topline data expected Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.